Elizabeth A. Giuliani

United States Military Academy — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index2.2kcitations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(6), Cancer-related Molecular Pathways(5), HIV/AIDS drug development and treatment(4), Computational Drug Discovery Methods(3), Click Chemistry and Applications(3)

Publications16 total

ChemInform Abstract: Potent, Non‐Thiol Inhibitors of Farnesyltransferase.
ChemInform·1999
Potent, non-thiol inhibitors of farnesyltransferase
Bioorganic & Medicinal Chemistry Letters·1998· 29 citedOpen Access
<i>N</i>-Arylalkyl Pseudopeptide Inhibitors of Farnesyltransferase
Journal of Medicinal Chemistry·1998· 24 citedOpen Access
<i>A Priori</i> Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site
Journal of Medicinal Chemistry·1996· 2 cited
Pseudodipeptide Inhibitors of Protein Farnesyltransferase
Journal of Medicinal Chemistry·1995· 32 citedOpen Access
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
Nature Medicine·1995· 537 cited
NMR studies of novel inhibitors bound to farnesyl‐protein transferase
Protein Science·1995· 41 citedOpen Access
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Proceedings of the National Academy of Sciences·1994· 285 citedOpen Access
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
Molecular and Cellular Biology·1994· 146 cited
Farnesyltransferase Inhibition Causes Morphological Reversion of <i>ras</i> -Transformed Cells by a Complex Mechanism That Involves Regulation of the Actin Cytoskeleton
Molecular and Cellular Biology·1994· 194 citedOpen Access
Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase
Journal of Medicinal Chemistry·1994· 110 citedOpen Access
Selective Inhibition of <i>ras</i> -Dependent Transformation by a Farnesyltransferase Inhibitor
Science·1993· 579 cited
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity
Journal of Medicinal Chemistry·1992· 41 citedOpen Access
Design and synthesis of HIV protease inhibitors. Variations of the carboxyterminus of the HIV protease inhibitor L-682,679
Journal of Medicinal Chemistry·1991· 41 citedOpen Access
L-687,908, a potent hydroxyethylene containing HIV protease inhibitor
Journal of Medicinal Chemistry·1991· 124 citedOpen Access
ChemInform Abstract: NEW TRICYCLIC ENAMINE DERIVATIVES WITH CNS DEPRESSANT PROPERTIES
Chemischer Informationsdienst·1975· 2 cited

Frequent Co-authors

S. J. DESOLMS(14), Samuel Graham(11), Nancy E. Kohl(8), Scott D. Mosser(8), Allen Oliff(6), W. Wayt Gibbs(5), David L. Pompliano(4), Elaine Rands(4), Paul L. Darke(4), Kenneth S. Koblan(3), Joseph P. Vacca(3), James P. Guare(3), Michael J. Breslin(3), Robert L. Smith(2), Charles A. Omer(2), Michael W. Conner(2), Neville J. Anthony(2), Joseph P. Davide(2), Kelly Hamilton(2), Steven D. Young(2)